Previous 10 | Next 10 |
AcelRx Still Gets Little Valuation For Dsuvia AcelRx is ready to launch Dsuvia, its proprietary sublingual formulation of sufentanil. Dsuvia was developed to be a safer, faster-acting opioid alternative to intravenous morphine for acute pain in hospital settings. It relives pain faster t...
AcelRx Pharmaceuticals ( ACRX ) has decided to "Go-It-Alone" for their U.S. commercial launch for DSUVIA. Some investors might be disappointed that the company didn't partner with big pharma. However, I think the decision to go solo will benefit the company in the long term. Still, I had a few...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t...
REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results after market close on Thursday, March 7th, 2019 . AcelRx management will ...
HENDERSON, NV / ACCESSWIRE / February 19, 2019 / Biotechnology is coming back strong in 2019 as the iShares Nasdaq Biotechnology Index's 16% surge higher during the first month and a half of this new year shows. There are several companies in the space we think are worth a look: BioRestorat...
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. It's no longer a question of simply creating treatment options and offering ...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix...
The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am...
REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a presentation about...
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...